Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties

Abstract

Objective:

To evaluate and update the evidence for the measurement properties of the Psoriatic Arthritis Impact of Disease (PsAID12) questionnaire to measure health-related quality of life (HRQoL) in psoriatic arthritis (PsA).

Methods:

The PsAID12 psychometric evidence was gathered in a systematic literature review in PsA (registration number: CRD42016032546). The study quality was appraised using the Consensus-based Standards for the selection of health Measurement Instruments–Outcome Measures in Rheumatology (COSMIN-OMERACT) good methods check-list. Content validity, test–retest reliability, construct validity, longitudinal construct validity, discrimination, and thresholds of meaning were appraised. Additional analyses for construct validity, responsiveness, and sensitivity to change were conducted in available observational data sets after prespecified hypotheses were formulated.

Results:

Eight publications (129-474 patients) were analyzed. The PsAID12 fulfilled OMERACT criteria for content validity (patients and physicians endorsed content match with PsA HRQoL domain), feasibility (endorsed by patients and physicians), and test–retest reliability (intraclass correlation coefficient: 0.91-0.95). A priori construct validity hypotheses were mostly met: Psoriatic Arthritis Impact of Disease had high correlation with generic (r = 0.76-0.87) and PsA-specific HRQol measures (0.8), and with measures of physical function (0.66-0.72), work productivity (0.69-0.75), pain (0.83), and fatigue (0.84). Psoriatic Arthritis Impact of Disease had moderate-high correlation with measures of patient global (0.49-0.84) and dermatologic HRQoL (0.36-0.53). Correlations were higher with generic HRQoL measured by short form-36 physical component score (0.47-0.73) versus short form-36 mental component score (0.22-0.60). Three studies confirmed known group validity of PsAID12 according to PsA disease activity. Psoriatic Arthritis Impact of Disease discriminated between change groups in 2 longitudinal studies (standardized response mean: 0.74-0.91, 53 and 105 patients). The minimal clinically important improvement was 3 and 1.4 points.

Conclusion:

Psoriatic Arthritis Impact of Disease had evidence for good content and construct validity, reliability, and longitudinal construct validity and is ready to evaluate in clinical trials.

Keywords

patient-reported outcome psoriasis psoriatic arthritis psychosocial impact quality of life systematic review

Get full access to this article

View all access options for this article.

References

Coates

Kavanaugh

Mease

, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.

Gossec

Smolen

Ramiro

, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499–510.

Mayo

. ISOQOL Dictionary of Quality of Life and Health Outcomes Measurement. ISOQOL; 2015.

Orbai

De Wit

Mease

, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017;76(4): 673–680.

Gladman

Mease

Strand

, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007;34(5):1167–1170.

Kalyoncu

Ogdie

Campbell

, et al. Systematic literature review of domains assessed in psoriatic arthritis to inform the upate of the psoriatic arthritis core domain set.RMD Open. 2016;2:e000217.

McHorney

Ware

Raczek

. The MOS 36-item short form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–263.

Chiarotto

Ostelo

Boers

Terwee

. A systematic review highlights the need to investigate the content validity of patient-reported outcome measures for physical functioning in patients with low back pain. J Clin Epidemiol. 2018;95:73–93.

Tillett

Dures

Hewlett

, et al. A multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritis. J Rheumatol. 2017;44(10):1445–1452.

10.

Højgaard

Klokker

Orbai

, et al. A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a GRAPPA-OMERACT initiative. Semin Arthritis Rheum. 2018;47(5):654–665.

11.

The European League Against Rheumatism, Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire. https://www.eular.org/tools_products_.cfm

12.

De Wit

Berlo

Aanerud

, et al. European league against rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis. 2011;70(5):722–726.

13.

Boers

Kirwan

Tugwell

, et al. The OMERACT Handbook. https://omeract.org/resources

14.

Orbai

Holland

Leung

, et al. PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials. J Rheumatol. 2019;46(8):990–995.

15.

Tillett

Orbai

Ogdie

, et al. GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies [published online July 26, 2017]. Ann Rheum Dis. 2018;77(5):e23. doi:10.1136/annrheumdis-2017-212004. No abstract available. PMID: 28747326

16.

Mokkink

Terwee

Patrick

, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international delphi study.Qual Life Res. 2010;19(4):539–549.

17.

Holland

Tillett

Ogdie

, et al. Content and face validity of five candidate instruments for psoriatic arthritis randomized controlled trials: the PsA OMERACT core set workshop at the GRAPPA 2017 annual meeting. J Rheumatol Suppl. 2018;94:17–25.

18.

Prinsen

CAC

Vohra

Rose

, et al. How to select outcome measurement instruments for outcomes included in a “core outcome set”—a practical guideline. Trials. 2016;17:449. doi:10.1186/s13063-016-1555-2.

19.

McKenna

Doward

Whalley

, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004;63(2):162–169.

20.

Holland

Tillett

Korendowych

, et al. Validation of the psoriatic arthritis impact of disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. Ann Rheum Dis. 2018;77(3):343–347.

21.

Gorlier

Puyraimond-Zemmour

Coates

, et al. How to define remission and low disease activity in psoriatic arthritis? an analysis of 419 patients with a double perspective, based on composite scores and patients’ and physicians’ perspectives [abstract]. Arthritis Rheumatol. 2018;70(suppl 10).

22.

Webster

Cella

Yost

. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.

23.

FitzGerald

Helliwell

Mease

, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis. 2012;71(3):358–362.

24.

Gossec

De Wit

Kiltz

, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012–1019.

25.

De Wit

Kvien

Gossec

. Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. RMD Open. 2015;1(1):e000129.

26.

Salaffi

Di Carlo

Carotti

Farah

Gutierrez

.The psoriatic arthritis impact of disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version. Ther Clin Risk Manag. 2016;12:631–642.

27.

Di Carlo

Becciolini

Lato

Crotti

Favalli

Salaffi

. The 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in a clinical setting. J Rheumatol. 2017;44(3):279–285.

28.

Queiro

Cañete

Montilla

, et al. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther. 2017;19(1):72.

29.

Puyraimond-Zemmour

Etcheto

Fautrel

, et al. Asssociations between five important domains of health and the patient acceptable symptom state in rheumatoid arthritis and psoriatic arthritis: a cross-sectional study of 977 patients. Arthritis Care Res. 2017;69(10):1504–1509.

30.

Theander

Husmark

Alenius

, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407–413.

31.

Haddad

Thavaneswaran

Ruiz-Arruza

, et al. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res. 2015;67(6):842–847.

32.

Perrotta

Marchesoni

Lubrano

. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol. 2016;43(2):350–355.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB